<DOC>
	<DOC>NCT00584493</DOC>
	<brief_summary>The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.</brief_summary>
	<brief_title>Treatment Use Study for Advanced Melanoma.</brief_title>
	<detailed_description>This is an expanded access trial that canceled prior to enrolling patients.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Advanced melanoma with life expectancy of at least 6 months. Melanoma must be considered unresectable. Patients with stable, treated brain mets must be stable clinically and radiographically and off steroids for at least one month. Patients must not be eligible for participation in any ongoing CP675,206 clinical studies currently open for enrollment. History of chronic inflammatory or autoimmune disease. History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, active colitis, history of diverticulitis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>